Mobile

Cilengitide (EMD121974) and temozolomide with concomitant radiation therapy, followed by cilengitide and temozolomide maintenance therapy in subjects with newly diagnosed glioblastoma multiforme – a m...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004849-18

Cilengitide (EMD121974) and temozolomide with concomitant radiation therapy, followed by cilengitide and temozolomide maintenance therapy in subjects with newly diagnosed glioblastoma multiforme – a multicenter, open-label, uncontrolled Phase I/IIa study

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this exploratory study is to estimate the percentage of subjects who survived 6 months without disease progression (6-month PFS).

Critère d'inclusion

  • Newly diagnosed Glioblastoma (Astrocytoma, WHO grade IV)

Liens